DK1796658T3 - Dopaminerge mimetika - Google Patents

Dopaminerge mimetika Download PDF

Info

Publication number
DK1796658T3
DK1796658T3 DK05799591.2T DK05799591T DK1796658T3 DK 1796658 T3 DK1796658 T3 DK 1796658T3 DK 05799591 T DK05799591 T DK 05799591T DK 1796658 T3 DK1796658 T3 DK 1796658T3
Authority
DK
Denmark
Prior art keywords
hydroxybutyrate
brain
eeg
ketosis
changes
Prior art date
Application number
DK05799591.2T
Other languages
English (en)
Inventor
Keith Frank Martin
David John Heal
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of DK1796658T3 publication Critical patent/DK1796658T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

1. Ketogent materiale, der er valgt blandt (R)-3-hydroxybutyrat, oligomer (R)-3-hydroxybutyrat og estere af (R)-3-hydroxybutyrat med glycerol eller (R)-butan-l,3-diol, til anvendelse til at give akut symptomatisk lindring for symptomer på Parkinsons sygdom som følge af dopamindeficiens i hjernen ved administration med en dosis på 50 til 1000 mg/kg legemsvægt pr. dag til frembringelse af en ketose, således at den samlede koncentration af acetoacetat og (R)-3-hydroxybutyrat i blodet hæves til mellem 0,5 og 8 mM; hvilket materiale er kendetegnet ved, at administrationen tilvejebringer en terapeutisk effektiv dosis af det ketogene materiale til akut symptomatisk lindring af én eller flere af symptomerne på motorisk syndrom ved bradykinesi (langsomme bevægelser), dyskinesi (unormale bevægelser), akinesi (stivhed), hviletremor, postural instabilitet og talesvigt; hvor disse symptomer reduceres i tidsrummet med ketose, og hvor den symptomatiske lindring indtræder inden for op til to timer efter påbegyndelse af ketose.
DK05799591.2T 2004-09-21 2005-09-21 Dopaminerge mimetika DK1796658T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61130204P 2004-09-21 2004-09-21
PCT/US2005/033860 WO2006034361A2 (en) 2004-09-21 2005-09-21 Dopaminergic mimetics

Publications (1)

Publication Number Publication Date
DK1796658T3 true DK1796658T3 (da) 2016-06-27

Family

ID=36090656

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05799591.2T DK1796658T3 (da) 2004-09-21 2005-09-21 Dopaminerge mimetika

Country Status (5)

Country Link
US (7) US20070281892A1 (da)
EP (1) EP1796658B1 (da)
DK (1) DK1796658T3 (da)
ES (1) ES2574557T3 (da)
WO (1) WO2006034361A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2459624C2 (ru) 2007-04-12 2012-08-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Защитные композиции от ишемии/реперфузии и способы применения
US20140371544A1 (en) * 2013-06-14 2014-12-18 Medtronic, Inc. Motion-based behavior identification for controlling therapy
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US20230151395A1 (en) * 2019-01-17 2023-05-18 Ioi Oleo Gmbh Method for producing glycerides of hydroxycarboxylic acids
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637726A (da) * 1962-09-26
US3665075A (en) * 1970-08-07 1972-05-23 American Cyanamid Co Thozalinone as an antiparkinson agent
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
DE2733202A1 (de) * 1976-08-04 1978-02-09 Agroferm Ag Verfahren zur herstellung der d(-)-3-hydroxybuttersaeure
US4067999A (en) * 1976-12-15 1978-01-10 Food Technology Products Control of hemorrhagic enteritis in turkeys
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
FR2521857B1 (fr) * 1982-02-23 1985-10-31 Solvay Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
US4701443A (en) * 1983-03-22 1987-10-20 Baxter Travenol Laboratories, Inc. Nutrient polyesters
EP0215138B1 (fr) * 1985-09-06 1991-01-16 Societe Des Produits Nestle S.A. Préservation des tissus vivants
GB8525666D0 (en) * 1985-10-17 1985-11-20 Ici Plc Chemical process
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
WO1987003809A1 (en) * 1985-12-20 1987-07-02 Veech Richard L Preparation of electrolyte solutions and containers
US5126373A (en) * 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
US4997976A (en) * 1988-11-15 1991-03-05 Henri Brunengraber Use of 1,3-butanediol acetoacetate in parenteral oral nutrition
US5292774A (en) * 1988-07-26 1994-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substitution fluid preparation comprising 3-hydroxy-butyric acid (β-hydroxybutric acid) and its salts
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
EP0522422A3 (en) * 1991-07-01 1993-03-17 Mitsubishi Kasei Corporation Process for producing a biodegradable polymer
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
WO1995009144A1 (en) * 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
US5912269A (en) * 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CA2317314C (en) * 1998-01-07 2003-12-30 Metabolix, Inc. Animal nutrition compositions
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
CA2227706C (en) * 1998-01-21 2010-08-03 Patrick Pageat Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
WO2002051395A1 (en) * 1998-05-28 2002-07-04 Codon Pharmaceuticals, Inc. Treatment of neurodegenerative diseases
DE69922206T2 (de) * 1998-07-22 2005-11-24 Metabolix, Inc., Cambridge Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
CN1273129C (zh) * 1998-09-15 2006-09-06 英国技术集团国际有限公司 治疗组合物(ⅱ)
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP2319508A1 (en) * 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20020132846A1 (en) * 2001-02-26 2002-09-19 Caleb Stone Use of gamma substituted gamma-butyrolactones to increase levels of their corresponding substituted gamma-hydroxybutyrate derivatives in humans
US6670378B2 (en) * 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
EP1605950A4 (en) * 2003-03-06 2008-01-09 Accera Inc NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS
EP1778212A4 (en) * 2004-07-23 2010-12-08 Btg Int Ltd SACCHARIDES CETOGENES
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition

Also Published As

Publication number Publication date
ES2574557T3 (es) 2016-06-20
WO2006034361A2 (en) 2006-03-30
US20210077440A1 (en) 2021-03-18
US20170035712A1 (en) 2017-02-09
EP1796658A4 (en) 2007-12-12
EP1796658A2 (en) 2007-06-20
US20180338938A1 (en) 2018-11-29
US20150141511A1 (en) 2015-05-21
US20070281892A1 (en) 2007-12-06
EP1796658B1 (en) 2016-03-30
US20230165817A1 (en) 2023-06-01
US20110065656A1 (en) 2011-03-17
WO2006034361A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
US20230165817A1 (en) Dopaminergic mimetics
US20220202760A1 (en) Cns modulators
US20220347134A1 (en) Treatment of adhd
Meier et al. Idebenone: an emerging therapy for Friedreich ataxia
Martinotti et al. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2017014284A (ja) プテロスチルベンの抗不安効果
Elgün et al. Increased serum arginase activity in depressed patients
US20220387424A1 (en) Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent
WO2002051395A1 (en) Treatment of neurodegenerative diseases
EP0341895B1 (en) Amino acids in the treatment of neurodegenerative disorders
Rinne et al. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor
Thornton et al. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man
EP2556833B1 (en) Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof
US20170367995A1 (en) Treatment of early stage parkinson's disease with a hydroxytyrosol-containing polyphenol formulation
US20240307377A1 (en) Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent
US20240307376A1 (en) Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent
HU213112B (en) Process for preparing antidepressive pharmaceutical preparations
French Potential Anticonvulsant Properties of the Three Major Ketone Bodies Elevated During the Ketogenic Diet
WO1994015603A1 (fr) Utilisation de l'idazoxan et ses derives pour le traitement de demence senile du type alzheimer